This shortcut to going public is making a comeback after an epic bust. What investors need to know.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2025
0mins
Should l Buy HIMS?
Source: MarketWatch
SPAC Market Recovery: Investors are increasingly interested in special-purpose acquisition companies (SPACs) again, three years after a significant downturn following the pandemic boom.
Record Activity in 2023: In 2023, 71 SPACs have entered the market, surpassing the total number from 2022, with raised funds exceeding those from three years ago.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
7 Hold
3 Sell
Hold
Current: 23.480
Low
29.00
Averages
42.88
High
85.00
Current: 23.480
Low
29.00
Averages
42.88
High
85.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Shares Surge After Hims Withdraws Weight-Loss Pill
- Significant Stock Surge: Novo Nordisk shares rose over 8% on Monday, reaching a market peak, primarily driven by Hims' withdrawal of its $49 compounded weight-loss pill, indicating a rebound in market confidence towards Novo.
- Legal Pressure Impact: Hims announced the discontinuation of the drug on Saturday under legal pressure from Novo and the FDA, reflecting the regulatory body's strict oversight of unauthorized compounded medications, which may further influence market competition dynamics.
- Market Value Fluctuation: Following a loss of approximately $50 billion in market value last week due to unprecedented pricing pressures, the stock rebound indicates renewed investor confidence, despite the company's forecast of a potential 13% decline in revenue and profits by 2026.
- Intensified Competition: With Eli Lilly leading in U.S. prescription trends, Novo Nordisk faces increasing competitive pressure, particularly in the high-margin obesity drug market, suggesting that future market dynamics will significantly impact its performance.
See More
Hims & Hers Super Bowl Ad Sparks Controversy Over Cancer Test
- Ad Controversy: The Super Bowl ad by Hims & Hers has sparked widespread debate over the reliability and ethical implications of its new cancer detection product, which claims to detect over 50 types of cancer before symptoms appear.
- Accuracy Concerns: Initial results indicate that the test only detects about 40% of cancers, meaning it may miss more than half of cases, potentially giving patients a false sense of reassurance about their health status.
- Mixed Market Response: Hims & Hers reported an EPS of 6 cents in its Q3 earnings, missing estimates, although its revenue of $598.97 million exceeded expectations; however, the company’s guidance for Q4 revenue fell below consensus, reflecting mixed performance.
- Pricing and Regulatory Challenges: The test is priced at $700, representing a 25% discount from the manufacturer's list price, but Grail has requested FDA approval under a stringent regulatory pathway, adding risks to its future market rollout.
See More
Hims Halts Sales of Wegovy Copycat Following FDA Scrutiny
- Regulatory Pressure Halts Sales: Hims announced the cessation of its $49 compounded semaglutide pill following FDA scrutiny, demonstrating the company's swift response to legal threats, even as retail sentiment remains optimistic.
- FDA Action Raises Legal Risks: The FDA plans to restrict access to GLP-1 ingredients in compounded drugs and refer Hims to the Department of Justice, indicating significant compliance challenges that could impact the company's future market performance.
- Competitors Push Back: Novo Nordisk and Eli Lilly strongly criticized Hims' compounded drug as illegal, threatening legal action to protect their intellectual property, which may intensify market competition and affect Hims' brand image.
- Market Sentiment Remains Bullish: Despite Hims' stock price dropping about 30% year-to-date, retail investor sentiment on Stocktwits is still 'extremely bullish', reflecting confidence in the company's future potential and possibly attracting more investor attention in the short term.
See More
Dow Jones Surpasses 50,000 for the First Time
- Historic Dow Close: The Dow Jones Industrial Average closed above 50,000 for the first time, surging approximately 2.5%, which signifies a notable improvement in market sentiment and may attract more investors to the U.S. stock market.
- Asia-Pacific Market Rebound: Japan's Nikkei jumped over 4%, primarily benefiting from the ruling LDP securing a two-thirds majority in the lower house, indicating potential for looser fiscal policies that could stimulate economic growth.
- Systematic Selling Pressure: Goldman Sachs anticipates that selling pressure from systematic funds could persist following the S&P 500 breaching a short-term CTA sell trigger, estimating around $33 billion in selling this week, which may further exacerbate market volatility.
- Surge in Capital Expenditure: Alphabet, Amazon, Meta, and Microsoft plan to invest a combined $650 billion in 2026 for data centers and chips, representing a roughly 60% increase from 2025, which will drive long-term growth potential in related sectors.
See More
Worst Performing Large-Cap Stocks Last Week
- Stellantis Loss Warning: Stellantis (NYSE:STLA) plummeted 26.24% this week after the company warned of a full-year net loss, significantly eroding investor confidence and potentially impacting future financing capabilities.
- Gartner Earnings Miss: Gartner (NYSE:IT) fell 25.41% this week following the release of its fourth-quarter financial results and a downward revision of its FY26 guidance, with analysts' pessimistic outlook likely to exert further pressure on the stock.
- Reddit Stock Decline: Reddit (NYSE:RDDT) dropped 23.10% this week as multiple analysts lowered their price forecasts, reflecting market concerns over its profitability and potentially hindering its financing and expansion plans.
- Analyst Downgrades: Several analysts adjusted their price targets downward for these companies, indicating a widespread bearish sentiment regarding their future performance, which may lead investors to reassess their portfolios.
See More
Hims & Hers Halts Compounded Semaglutide Pill Offering
- Decision to Halt Sales: Hims & Hers has decided to cease offering its compounded semaglutide pill priced at $49 per month just days after its launch, reflecting the company's responsiveness to stakeholder feedback, although this may negatively impact its market share and stock price.
- FDA Warning Impact: The U.S. Food and Drug Administration (FDA) has warned it will restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, prompting Hims & Hers to respond to regulatory pressures that could lead to stricter compliance requirements for the company.
- Escalating Legal Threats: Novo Nordisk has issued legal threats against Hims & Hers, accusing the company of deceptive marketing practices in the sale of compounded drugs, which could result in significant financial liabilities for Hims & Hers amid ongoing litigation.
- Stock Price Volatility Risk: Following the launch of the compounded drug, Hims & Hers' stock experienced a surge; however, due to legal disputes and regulatory pressures, the stock now faces downward risks, necessitating investor vigilance regarding the company's future compliance and market strategies.
See More
Novo Nordisk Shares Surge After Hims Withdraws Weight-Loss Pill
- Significant Stock Surge: Novo Nordisk shares rose over 8% on Monday, reaching a market peak, primarily driven by Hims' withdrawal of its $49 compounded weight-loss pill, indicating a rebound in market confidence towards Novo.
- Legal Pressure Impact: Hims announced the discontinuation of the drug on Saturday under legal pressure from Novo and the FDA, reflecting the regulatory body's strict oversight of unauthorized compounded medications, which may further influence market competition dynamics.
- Market Value Fluctuation: Following a loss of approximately $50 billion in market value last week due to unprecedented pricing pressures, the stock rebound indicates renewed investor confidence, despite the company's forecast of a potential 13% decline in revenue and profits by 2026.
- Intensified Competition: With Eli Lilly leading in U.S. prescription trends, Novo Nordisk faces increasing competitive pressure, particularly in the high-margin obesity drug market, suggesting that future market dynamics will significantly impact its performance.
See More
Hims & Hers Super Bowl Ad Sparks Controversy Over Cancer Test
- Ad Controversy: The Super Bowl ad by Hims & Hers has sparked widespread debate over the reliability and ethical implications of its new cancer detection product, which claims to detect over 50 types of cancer before symptoms appear.
- Accuracy Concerns: Initial results indicate that the test only detects about 40% of cancers, meaning it may miss more than half of cases, potentially giving patients a false sense of reassurance about their health status.
- Mixed Market Response: Hims & Hers reported an EPS of 6 cents in its Q3 earnings, missing estimates, although its revenue of $598.97 million exceeded expectations; however, the company’s guidance for Q4 revenue fell below consensus, reflecting mixed performance.
- Pricing and Regulatory Challenges: The test is priced at $700, representing a 25% discount from the manufacturer's list price, but Grail has requested FDA approval under a stringent regulatory pathway, adding risks to its future market rollout.
See More
Hims Halts Sales of Wegovy Copycat Following FDA Scrutiny
- Regulatory Pressure Halts Sales: Hims announced the cessation of its $49 compounded semaglutide pill following FDA scrutiny, demonstrating the company's swift response to legal threats, even as retail sentiment remains optimistic.
- FDA Action Raises Legal Risks: The FDA plans to restrict access to GLP-1 ingredients in compounded drugs and refer Hims to the Department of Justice, indicating significant compliance challenges that could impact the company's future market performance.
- Competitors Push Back: Novo Nordisk and Eli Lilly strongly criticized Hims' compounded drug as illegal, threatening legal action to protect their intellectual property, which may intensify market competition and affect Hims' brand image.
- Market Sentiment Remains Bullish: Despite Hims' stock price dropping about 30% year-to-date, retail investor sentiment on Stocktwits is still 'extremely bullish', reflecting confidence in the company's future potential and possibly attracting more investor attention in the short term.
See More
Dow Jones Surpasses 50,000 for the First Time
- Historic Dow Close: The Dow Jones Industrial Average closed above 50,000 for the first time, surging approximately 2.5%, which signifies a notable improvement in market sentiment and may attract more investors to the U.S. stock market.
- Asia-Pacific Market Rebound: Japan's Nikkei jumped over 4%, primarily benefiting from the ruling LDP securing a two-thirds majority in the lower house, indicating potential for looser fiscal policies that could stimulate economic growth.
- Systematic Selling Pressure: Goldman Sachs anticipates that selling pressure from systematic funds could persist following the S&P 500 breaching a short-term CTA sell trigger, estimating around $33 billion in selling this week, which may further exacerbate market volatility.
- Surge in Capital Expenditure: Alphabet, Amazon, Meta, and Microsoft plan to invest a combined $650 billion in 2026 for data centers and chips, representing a roughly 60% increase from 2025, which will drive long-term growth potential in related sectors.
See More
Worst Performing Large-Cap Stocks Last Week
- Stellantis Loss Warning: Stellantis (NYSE:STLA) plummeted 26.24% this week after the company warned of a full-year net loss, significantly eroding investor confidence and potentially impacting future financing capabilities.
- Gartner Earnings Miss: Gartner (NYSE:IT) fell 25.41% this week following the release of its fourth-quarter financial results and a downward revision of its FY26 guidance, with analysts' pessimistic outlook likely to exert further pressure on the stock.
- Reddit Stock Decline: Reddit (NYSE:RDDT) dropped 23.10% this week as multiple analysts lowered their price forecasts, reflecting market concerns over its profitability and potentially hindering its financing and expansion plans.
- Analyst Downgrades: Several analysts adjusted their price targets downward for these companies, indicating a widespread bearish sentiment regarding their future performance, which may lead investors to reassess their portfolios.
See More
Hims & Hers Halts Compounded Semaglutide Pill Offering
- Decision to Halt Sales: Hims & Hers has decided to cease offering its compounded semaglutide pill priced at $49 per month just days after its launch, reflecting the company's responsiveness to stakeholder feedback, although this may negatively impact its market share and stock price.
- FDA Warning Impact: The U.S. Food and Drug Administration (FDA) has warned it will restrict GLP-1 active pharmaceutical ingredients for non-FDA-approved compounded drugs, prompting Hims & Hers to respond to regulatory pressures that could lead to stricter compliance requirements for the company.
- Escalating Legal Threats: Novo Nordisk has issued legal threats against Hims & Hers, accusing the company of deceptive marketing practices in the sale of compounded drugs, which could result in significant financial liabilities for Hims & Hers amid ongoing litigation.
- Stock Price Volatility Risk: Following the launch of the compounded drug, Hims & Hers' stock experienced a surge; however, due to legal disputes and regulatory pressures, the stock now faces downward risks, necessitating investor vigilance regarding the company's future compliance and market strategies.
See More
